Gemzar Approved for Recurrent Ovarian Cancer

Already sanctioned for several other malignancies

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

WEDNESDAY, July 19, 2006 (HealthDay News) -- Eli Lilly & Co.'s popular cancer drug Gemzar has received U.S. Food and Drug Administration approval to be used as a treatment for recurrent ovarian cancer, the company said.

This new approval covers the use of Gemzar in combination with carboplatin to treat women who've suffered an ovarian cancer relapse at least six months after treatment, the Associated Press reported.

Ovarian cancer recurs in 90 percent of women who are diagnosed and treated, according to Lilly. There will be an estimated 20,180 new cases of ovarian cancer in the United States this year, the American Cancer Society says.

Gemzar already had FDA approval to treat breast cancer, lung cancer, and pancreatic cancer, the AP reported.

More information

To learn about ovarian cancer, visit the U.S. National Cancer Institute.

Last Updated: